Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00003850 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

NIH

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: thalidomide

Sponsor

National Cancer Institute (NCI)